Travere Therapeutics (NASDAQ:TVTX – Get Free Report) will be announcing its earnings results after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.87) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last issued its quarterly earnings results on Monday, May 6th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). The firm had revenue of $41.40 million during the quarter, compared to analyst estimates of $43.46 million. Travere Therapeutics had a negative return on equity of 238.06% and a negative net margin of 87.94%. The firm’s revenue for the quarter was up 34.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.27) EPS. On average, analysts expect Travere Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Travere Therapeutics Trading Down 3.2 %
Shares of NASDAQ TVTX traded down $0.33 during midday trading on Tuesday, reaching $9.86. The stock had a trading volume of 195,688 shares, compared to its average volume of 1,220,574. The firm has a market cap of $750.63 million, a price-to-earnings ratio of -4.85 and a beta of 0.77. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $17.57. The company has a debt-to-equity ratio of 5.10, a quick ratio of 2.75 and a current ratio of 2.78. The company’s 50 day moving average price is $8.12 and its 200 day moving average price is $7.74.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on Travere Therapeutics
About Travere Therapeutics
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Featured Stories
- Five stocks we like better than Travere Therapeutics
- Dividend Capture Strategy: What You Need to Know
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- High Flyers: 3 Natural Gas Stocks for March 2022
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.